Adaptive Biotechnologies to Present at the UBS Genomics 2.0 and Medtech Innovations Summit
August 10 2020 - 8:05AM
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a
commercial stage biotechnology company that aims to translate the
genetics of the adaptive immune system into clinical products to
diagnose and treat disease, today announced it will be
participating in the upcoming UBS Genomics 2.0 and Medtech
Innovations Virtual Summit.
Adaptive Biotechnologies’ management is scheduled
to participate in a fireside chat on Tuesday, August 11th at 11:00
a.m. Pactific Time / 2:00 p.m. Eastern Time. Interested parties may
access a live and archived webcast of the presentation on the
“Investors” section of the company website at:
www.adaptivebiotech.com.
About Adaptive
Biotechnologies
Adaptive Biotechnologies is a commercial-stage
biotechnology company focused on harnessing the inherent biology of
the adaptive immune system to transform the diagnosis and treatment
of disease. We believe the adaptive immune system is nature’s most
finely tuned diagnostic and therapeutic for most diseases, but the
inability to decode it has prevented the medical community from
fully leveraging its capabilities. Our proprietary immune medicine
platform reveals and translates the massive genetics of the
adaptive immune system with scale, precision and speed to develop
products in life sciences research, clinical diagnostics, and drug
discovery. We have two commercial products, and a robust clinical
pipeline to diagnose, monitor and enable the treatment of diseases
such as cancer, autoimmune conditions and infectious diseases. Our
goal is to develop and commercialize immune-driven clinical
products tailored to each individual patient. For more information,
please visit adaptivebiotech.com and follow us on
www.twitter.com/adaptivebiotech.
Investor Contact:Carrie
Mendivilinvestors@adaptivebiotech.com
Media Contact:Beth
Keshishianmedia@adaptivebiotech.com
Adaptive Biotechnologies (NASDAQ:ADPT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Adaptive Biotechnologies (NASDAQ:ADPT)
Historical Stock Chart
From Apr 2023 to Apr 2024